RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Retrieved on:
Monday, November 14, 2022
Cell, Awareness, Thallium, Literature, Acceleration, Half-life, Caesium, Americium, Infection, TBI, International Journal of Molecular Sciences, La Trobe Institute for Molecular Science, Face, Strategic National Stockpile, Radiation, Survival, Government, Radiation exposure, B cell, Iodine, FDA, Filgrastim, Apsis, TEL, Chemoradiotherapy, Head, Mouse, Acute radiation syndrome, TNF, Total body irradiation, Safety, Extrapyramidal system, Nutrient, Toxicity, Inflammation, Homeland, Redhill, Chronic radiation syndrome, Opaganib, Plutonium, Animal, DTPA, Stem cell, Company, Nasdaq, Potassium iodide, Canadian International Council, Disease, Radiation damage, COVID-19, Bone marrow, Curium, MCM, Medical imaging, Pharmaceutical industry, Food preservation, Prussian blue (disambiguation)
The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
Key Points:
- The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
- Much of the damage caused by radiation exposure is caused by inflammation secondary to the effects of ionizing radiation itself known as Acute Radiation Syndrome.
- Again, opaganib was not associated with a diminished tumor response to fractionated radiation treatment and increased weight loss from radiation treatment was not observed.
- Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv .